Transcriptic, the cloud-based biotech lab that tests for experimental drugs automation and robotics, has become a key platform for many biotech companies in Silicon Valley.
The platform has been particularly useful for many of the biotech companies now coming out of Y Combinator. These startups don’t have the deep pockets of big pharma and need a low-cost solution that produces rapid results. Transcriptic has offered a $20,000 credit to Notable Labs, AtomWise and other YC-backed startups to help spark the drug discovery market within the valley.
It takes an average of 12 years and billions of dollars to get a new drug on the market. According to Transcriptic, its services enable scientists to work remotely with a wide swath of data and automated equipment that can produce low-cost results in days. While there’s a lot more to getting a drug on the market, this could greatly reduce the time and cost involved in getting life-saving drugs to market faster.
Transcriptic recently moved into a new 22,000 square-foot facility in Menlo Park, California. This gives it a bit more room to grow and the ability to introduce additional services. We caught up with founder Max Hodak to check out the new space.